Bcl2-associated athanogene 3 (BAG3) protein is a member of BAG family of co-chaperones that interacts with the ATPase domain of the heat shock protein (Hsp) 70 through BAG domain (110–124 amino acids) ...

WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative clinical-stage gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) ...

BAG3 DCM is a devastating monogenic heart disease affecting more than 70,000 patients in the U.S., Europe, and U.K., with almost 25% of patients requiring a heart transplant AFTX-201 is a potential ...

The phase 1/2 UPBEAT trial is currently evaluating a single intravenous infusion of AFTX-201 in adults with genetically confirmed BAG3-associated dilated cardiomyopathy. The Food and Drug ...

BAG3 DCM is a devastating genetic heart disease caused by a mutation in the BAG3 gene and resulting in loss of heart function at a young age; despite current standard of care, almost 25% of patients ...

As if a heart attack weren’t traumatic enough, the tissue injury that follows can cause irreparable damage to heart muscle, increasing an individual’s risk of heart failure occurring later. With the ...

Renovacor is developing proprietary AAV-based gene therapies for BAG3 gene mutation-associated CV and CNS diseases. The company’s lead program is BAG3 mutation-associated dilated cardiomyopathy. The ...

The inability of cells to eliminate damaged proteins and organelles following the blockage of a coronary artery and its subsequent re-opening with angioplasty or medications - a sequence known as ...

(Philadelphia, PA) - The inability of cells to eliminate damaged proteins and organelles following the blockage of a coronary artery and its subsequent re-opening with angioplasty or medications - a ...

Affinia Therapeutics to Present AFTX-201 for BAG3-Associated Dilated Cardiomyopathy (DCM) and Highlight Proprietary Capsid Engineering and Manufacturing Data at the American Society of Gene & Cell ...